References

1. 1.
   LI M B， HE X Y，YANG X H，et al. Interpretation of report on cardiovascular health and diseases in China 2023［J］.Chin J Cardiovasc Med，2024，29（4）：305-324.
2. 2.
   HE X，DENG J，YU X J，et al. Activation of M3AChR （type 3 muscarinic acetylcholine receptor） and Nrf2 （nuclear factor erythroid 2-related factor 2） signaling by choline alleviates vascular smooth muscle cell phenotypic switching and vascular remodeling［J］.Arterioscler Thromb Vasc Biol，2020，40 （11）：2649-2664.
3. 3.
   BOCHATON-PIALLAT M L，BÄCK M. Novel concepts for the role of smooth muscle cells in vascular disease：Towards a new smooth muscle cell classification［J］.Cardiovasc Res，2018，114 （4）：477-480.
4. 4.
   WU Q，YU J H，CAO S S，et al.Effect of Shexiang Tongxin dropping pill on renin-angiotensin-aldosterone system in essential hypertension［J］.Chin Arch Tradit Chin Med，2016，34（6）：1351-1353.
5. 5.
   LU X，YAO J，LI C，et al. Shexiang Tongxin dropping pills promote macrophage polarization-induced angiogenesis against coronary microvascular dysfunction via PI3K/Akt/mTORC1 pathway［J］.Front Pharmacol，2022，13：840521.
6. 6.
   YANG S S.The study on the mechanism of promoting angiogenesis by Shexiang Tongxin dripping pills based on TGF-β₁/ALK1/Smad1/5 signaling pathway［D］.Harbin：Heilongjiang University of Traditional Chinese Medicine，2022.
7. 7.
   TSAI M H，LEE C W，HSU L F，et al.CO-releasing molecules CORM2 attenuates angiotensin Ⅱ-induced human aortic smooth muscle cell migration through inhibition of ROS/IL-6 generation and matrix metalloproteinases-9 expression［J］.Redox Biol，2017，12：377-388.
8. 8.
   WANG L， ZHOU B， ZHAO Z， et al. Body-mass index and obesity in urban and rural China：Findings from consecutive nationally representative surveys during 2004-18［J］.Lancet，2021，398（10294）：53-63.
9. 9.
   OHSHIMA K，MOGI M，NAKAOKA H，et al. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin Ⅱ type 2 receptor by angiotensin-（1-7） in improvement of vascular remodeling by angiotensin Ⅱ type 1 receptor blockade［J］.Hypertension，2014，63 （3）：e53-e59.
10. 10.
    ZHANG J，DONG J，MARTIN M，et al. AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension［J］.Am J Respir Crit Care Med，2018，198 （4）：509-520.
11. 11.
    JIAO X，YU H，DU Z，et al. Vascular smooth muscle cells specific deletion of angiopoietin-like protein 8 prevents angiotensin Ⅱ-promoted hypertension and cardiovascular hypertrophy［J］.Cardiovasc Res，2023，119 （9）：1856-1868.
12. 12.
    ALVES-FIGUEIREDO H，SILVA-PLATAS C，ESTRADA M，et al. Mitochondrial Ca²⁺ uniporter-dependent energetic dysfunction drives hypertrophy in heart failure［J］.JACC Basic Transl Sci，2024，9 （4）：496-518.
13. 13.
    YAO Y，HU C，SONG Q，et al.ADAMTS16 activates latent TGF-β， accentuating fibrosis and dysfunction of the pressure-overloaded heart［J］.Cardiovasc Res，2020，116 （5）：956-969.
14. 14.
    WANG J，ZHANG C，LI C，et al. MicroRNA-92a promotes vascular smooth muscle cell proliferation and migration through the ROCK/MLCK signalling pathway［J］.J Cell Mol Med，2019，23 （5）：3696-3710.
15. 15.
    ZHANG C，ZHAO Y X，ZHANG Y H，et al. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells［J］.Proc Natl Acad Sci USA，2010，107（36）：15886-15891.
16. 16.
    DAI H，JIANG L，XIAO Z，et al. ACE2-angiotensin-（1-7）-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension［J］.Nat Rev Cardiol，2015，12（6）：374.
17. 17.
    ZOU F，LI Y，ZHANG S，et al. DP1 （prostaglandin D（2） receptor 1） activation protects against vascular remodeling and vascular smooth muscle cell transition to myofibroblasts in angiotensin Ⅱ-induced hypertension in mice［J］.Hypertension，2022，79 （6）：1203-1215.
18. 18.
    WU N，ZHENG F，LI N，et al. RND3 attenuates oxidative stress and vascular remodeling in spontaneously hypertensive rat via inhibiting ROCK1 signaling［J］.Redox Biol，2021，48：102204.
19. 19.
    PARAJULI N，RAMPRASATH T，PATEL V B，et al. Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases［J］.Can J Physiol Pharmacol，2014，92 （7）：558-565.
20. 20.
    WU G， YU D L， LI L， et al.Influence mechanism of myocardial fibrosis and vascular regeneration of Shexiang Tongxin pills to syndrome of Qi deficiency and blood stasis in ischemic heart failure［J］.Chin J Exp Tradit Med Form，2021，27（1）：141-146.
21. 21.
    ZHANG M D，CUI X Y ，YUAN Y Y， et al. Mechanism of Shexiang Tongxin dropping pill in improving cardiac function in diabetic rat with myocardial infarction by promoting angiogenesis［J］.Tianjin J Tradit Chin Med，2022，39（8）：1043-1051.
22. 22.
    ZHU G X，ZUO J L，XU L，et al.Ginsenosides in vascular remodeling：Cellular and molecular mechanisms of their therapeutic action［J］.Pharmacol Res，2021，169：105647.
23. 23.
    YANG G S，ZHENG B，QIN Y，et al. Salvia miltiorrhiza-derived miRNAs suppress vascular remodeling through regulating OTUD7B/KLF4/NMHC Ⅱ_A axis［J］.Theranostics，2020，10 （17）：7787-7811.
24. 24.
    LI L J，GE H，CHEN X，et al. Effect of musk Tongxin dropping pills on vascular endothelial function and the Rho/ROCK signaling pathway in hypertensive rats［J］.J China Med Univ，2020，49（6）：485-489，504.